Cambridge Investment Research Advisors
LCTX icon

Cambridge Investment Research Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-23,552
Closed -$65K – 2034
2017
Q2 		$65K Buy
23,552
+1,143
+5% +$3.19K ﹤0.01% 1874
2017
Q1 		$68K Buy
22,409
+1,143
+5% +$3.25K ﹤0.01% 1719
2016
Q4 		$67K Buy
21,266
+7,144
+51% +$21.9K ﹤0.01% 1614
2016
Q3 		$48K Buy
+14,122
New +$39K ﹤0.01% 1702

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Destination Wealth Management
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Cambridge Investment Research Advisors's LCTX Position: Q3 2017 in Review

Cambridge Investment Research Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2017, closing a stake of 23,552 shares — an estimated $65K sold.

Cambridge Investment Research Advisors first reported a position in LCTX in Q3 2016 and held it in 4 quarters. The position peaked at $68K in Q1 2017. 102 funds tracked by Wall St. Rank hold LCTX as of Q3 2017.

  • Cambridge Investment Research Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 23,552 Lineage Cell Therapeutics shares in Q3 2017, an estimated $65K.
  • Cambridge Investment Research Advisors first reported a position in Lineage Cell Therapeutics in Q3 2016 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Lineage Cell Therapeutics position peaked at $68K in Q1 2017.
  • 102 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2017.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2017, filed 7 Nov 2017.